Skip to main content

Waldenstrom Macroglobulinemia

News
12/22/2021
Data from a real-world analysis on the role of ASCT in patients with WM was presented at the 2021 ASH Annual Meeting to review response outcomes, survival outcomes, and relapsed risk factors in patients with WM who underwent ASCT.
Data from a real-world analysis on the role of ASCT in patients with WM was presented at the 2021 ASH Annual Meeting to review response outcomes, survival outcomes, and relapsed risk factors in patients with WM who underwent ASCT.
Data from a real-world analysis...
12/22/2021
Oncology
Test Your Knowledge
11/17/2021
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a...
11/17/2021
Oncology
News
11/17/2021
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that...
11/17/2021
Oncology
qqqq
Test Your Knowledge
11/10/2021
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated...
11/10/2021
Oncology
News
11/10/2021
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up...
11/10/2021
Oncology
Videos
11/04/2019
Steven Treon, MD, PhD, FACP, FRCP, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Steven Treon, MD, PhD, FACP, FRCP, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Steven Treon, MD, PhD, FACP,...
11/04/2019
Oncology
12/18/2018
Patients with symptomatic, previously treated WM responded well to therapy with venetoclax, according results from a recent phase 2 clinical trial.
Patients with symptomatic, previously treated WM responded well to therapy with venetoclax, according results from a recent phase 2 clinical trial.
Patients with symptomatic,...
12/18/2018
Oncology
12/12/2018
The combination of ibrutinib and rituximab consistently outshined rituximab alone in the treatment of patients with WM, according to follow-up results from the iNNOVATE trial.
The combination of ibrutinib and rituximab consistently outshined rituximab alone in the treatment of patients with WM, according to follow-up results from the iNNOVATE trial.
The combination of ibrutinib and...
12/12/2018
Oncology